Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Giulia Frontini"'
Autor:
Andrea Doria, Luca Iaccarino, Gabriella Moroni, Renato Alberto Sinico, Mariele Gatto, Giulia Frontini, Marta Calatroni, Francesco Reggiani, Claudio Cruciani
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/5f19c28b0f464b13a1116a5d8ff8a53a
Autor:
Fabrizio Fabrizi, Maria F. Donato, Roberta Cerutti, Federica Invernizzi, Giulia Porata, Giulia Frontini, Francesca Raffiotta, Tullia De Feo, Carlo M. Alfieri, Pietro Lampertico, Giorgio Rossi, Piergiorgio Messa
Publikováno v:
Nefrología (English Edition), Vol 42, Iss 1, Pp 41-49 (2022)
Background and rationale: Chronic kidney disease remains an important risk factor for morbidity and mortality among LT recipients, but its exact incidence and risk factors are still unclear. Material and methods: We carried out a retrospective cohort
Externí odkaz:
https://doaj.org/article/69feab451b444aeea2fcfd0391d1747e
Autor:
Gabriella Moroni, Claudio Ponticelli, Giulia Frontini, Francesca Raffiotta, Giulia Porata, Marta Calatroni, Francesco Reggiani, Giovanni Banfi
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss 1 (2022)
Objectives Based on available data, the histological predictors of long-term outcome of lupus nephritis (LN) are not clearly defined. Aims of this retrospective study were: (i) to evaluate the change of chronicity index from the first to second kidne
Externí odkaz:
https://doaj.org/article/e966e3864fbf45e1bdb841cbd9fb5c0e
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. The disease generally runs an indolent course but may lead to ESRD in 20–30% of patients in 20 years or more after diagnosis. Patients with IgA nephropathy are ideal ca
Externí odkaz:
https://doaj.org/article/26e571edb30746e68843434b881f19ac
Autor:
Giulia Porata, Silvana Quaglini, Claudio Ponticelli, Francesco Reggiani, Valentina Binda, Giovanni Banfi, Lucia Sacchi, Francesca Raffiotta, Marta Calatroni, Gabriella Moroni, Giulia Frontini
Publikováno v:
Kidney360
BACKGROUND: A renewed interest for activity and chronicity indices as predictors of lupus nephritis (LN) outcome has emerged. Revised National Institutes of Health activity and chronicity indices have been proposed to classify LN lesions, but they sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7095d662a9e6ee4b6ea603e6446a00d
https://doi.org/10.34067/kid.0005512021
https://doi.org/10.34067/kid.0005512021
Autor:
Fabrizio Fabrizi, Giulia Porata, Roberta Cerutti, Rebeca García-Agudo, Cecilia Bellincioni, Sami Aoufi-Rabih, Giulia Frontini, Piergiorgio Messa
Publikováno v:
Clinics and Research in Hepatology and Gastroenterology. 44:905-912
Summary Background Patients on regular dialysis show a poor response to hepatitis B vaccine due to uremia. A recombinant HB vaccine (containing an improved adjuvant system AS04, HBV-AS04) has been licensed but the evidence on its efficacy and safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1b27c3c4a91d144d68d7708b68e0de
https://doi.org/10.1016/j.clinre.2020.01.010
https://doi.org/10.1016/j.clinre.2020.01.010
Autor:
Piergiorgio Messa, Maria Rosa Pozzi, Nicoletta Del Papa, Giulia Porata, Giulia Frontini, Gabriella Moroni, Paolo Fabbrini, Barbara Trezzi, Renato Alberto Sinico, Valentina Binda, Lorenzo Beretta
Publikováno v:
Journal of Nephrology. 33:1019-1025
Background: Belimumab (Benlysta) is currently approved for the treatment of active Lupus despite standard therapy. Few data are available on the efficacy of this drug in lupus nephritis (LN). Methods: 17 LN female followed in two Nephrology Italian U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b62c2aa835790405ff94aadc89f916d8
https://doi.org/10.1007/s40620-020-00706-3
https://doi.org/10.1007/s40620-020-00706-3
Autor:
Mariele Gatto, Francesca Radice, Francesca Saccon, Marta Calatroni, Giulia Frontini, Barbara Trezzi, Margherita Zen, Anna Ghirardello, Francesco Tamborini, Valentina Binda, Vincenzo L'Imperio, Andrea Doria, Augusto Vaglio, Renato Alberto Sinico, Gabriella Moroni, Luca Iaccarino
ObjectiveTo investigate second kidney biopsy as predictor of end-stage kidney disease (ESKD) in active lupus nephritis (LN).MethodsPatients with biopsy-proven LN (International Society of Nephrology/Renal Pathology Society 2003) who had undergone a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b837a81965ce78559da27935fb28e820
http://hdl.handle.net/11577/3452018
http://hdl.handle.net/11577/3452018
Publikováno v:
Clin J Am Soc Nephrol
Glucocorticoids and other immunosuppressants still represent the cornerstone drugs for the management of SLE (Systemic Lupus Erythematosus) and lupus nephritis. The refined use of these drugs over the years has allowed to obtain stable disease remiss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e010fc8acdcd89163c7118dfdeed6ef6
https://pubmed.ncbi.nlm.nih.gov/34162696
https://pubmed.ncbi.nlm.nih.gov/34162696
Autor:
Giulia Frontini, Francesco Tamborini, Giulia Porata, Anna Regalia, Valentina Binda, Gabriella Moroni
Publikováno v:
Clinical and experimental rheumatology. 40(5)
We aimed to identify the rates and predictors of chronic damage accrual and mortality in lupus nephritis (LN).We retrospectively measured SLICC/ACR Damage Index (SDI) in biopsy proven active LN with at least 5 years follow-up. We searched for the pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f69c7db4a30250a2dccd038a2af043f
https://pubmed.ncbi.nlm.nih.gov/34494962
https://pubmed.ncbi.nlm.nih.gov/34494962